AEG-1/MTDH/LYRIC in liver cancer

Advances in Cancer Research

Volumn 120, Issue , 2013, Pages 193-221

  Sarkar, Devanand ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AEG 1; Hepatocellular carcinoma; LSF; SND1; Transgenic mouse model

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; BEVACIZUMAB; CALGRANULIN A; CISPLATIN; CLAUDIN 4; CYTOCHROME P450 2B6; DIHYDRODIOL DEHYDROGENASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; FACTOR QUINOLINONE INHIBITOR 1; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LYMPHOID ENHANCER FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEASE; PLACEBO; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 7; SORAFENIB; STAPHYLOCOCCAL NUCLEASE DOMAIN CONTAINING 1; TETRASPANIN; THYMIDYLATE SYNTHASE; TRANSGELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

AEG 1 GENE; ALCOHOLISM; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MODEL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CHEMOEMBOLIZATION; COLONY FORMATION; DRUG EFFICACY; GENE OVEREXPRESSION; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYRIC GENE; METABOLIC SYNDROME X; METASTASIS; MOLECULARLY TARGETED THERAPY; MTDH GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ONCOGENE; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; RNA TRANSLATION; TRANSGENIC MOUSE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VIRUS CARCINOGENESIS;

AEG-1; HEPATOCELLULAR CARCINOMA; LSF; SND1; TRANSGENIC MOUSE MODEL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MUTATION; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880939050     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-401676-7.00007-3     Document Type: Chapter

References (84)

1. Bellahcene A., Castronovo V., Ogbureke K.U., Fisher L.W., Fedarko N.S. Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): Multifunctional proteins in cancer. Nature Reviews. Cancer 2008, 8:212-226.
2. Bembenek S.D., Tounge B.A., Reynolds C.H. Ligand efficiency and fragment-based drug discovery. Drug Discovery Today 2009, 14:278-283.
3. Boyault S., Rickman D.S., de Reynies A., Balabaud C., Rebouissou S., Jeannot E., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
4. Brechot C., Pourcel C., Louise A., Rain B., Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980, 286:533-535.
5. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
6. Brown D.M., Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004, 5:365-374.
7. Burger A.M., Zhang X., Li H., Ostrowski J.L., Beatty B., Venanzoni M., et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene 1998, 16:2459-2467.
8. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 2003, 348:1625-1638.
9. Caudy A.A., Ketting R.F., Hammond S.M., Denli A.M., Bathoorn A.M., Tops B.B., et al. A micrococcal nuclease homologue in RNAi effector complexes. Nature 2003, 425:411-414.
10. Chen D., Siddiq A., Emdad L., Rajasekaran D., Gredler R., Shen X.-N., et al. Insulin-like growth factor binding protein-7 (IGFBP7): A promising gene therapeutic for hepatocellular carcinoma (HCC). Molecular Therapy 2013, 21(4):758-766.
11. Chen D., Yoo B.K., Santhekadur P.K., Gredler R., Bhutia S.K., Das S.K., et al. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clinical Cancer Research 2011, 17:6693-6701.
12. Chen J., Zhang Z., Stebbins J.L., Zhang X., Hoffman R., Moore A., et al. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chemical Biology 2007, 2:329-336.
13. Donato F., Tagger A., Gelatti U., Parrinello G., Boffetta P., Albertini A., et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. American Journal of Epidemiology 2002, 155:323-331.
14. Dragani T.A. Risk of HCC: Genetic heterogeneity and complex genetics. Journal of Hepatology 2010, 52:252-257.
15. El-Serag H.B. Hepatocellular carcinoma. The New England Journal of Medicine 2011, 365:1118-1127.
16. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
17. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-468.
18. Emdad L., Lee S.G., Su Z.Z., Jeon H.Y., Boukerche H., Sarkar D., et al. Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:21300-21305.
19. Emdad L., Sarkar D., Su Z.Z., Randolph A., Boukerche H., Valerie K., et al. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: Implications for tumor progression and metastasis. Cancer Research 2006, 66:1509-1516.
20. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: From genes to environment. Nature Reviews. Cancer 2006, 6:674-687.
21. Feitelson M.A., Duan L.X. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. The American Journal of Pathology 1997, 150:1141-1157.
22. Georgiades C.S., Hong K., Geschwind J.F. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer Journal 2008, 14:117-122.
23. Gong Z., Liu W., You N., Wang T., Wang X., Lu P., et al. Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma. Oncology Reports 2012, 27:2073-2079.
24. Grant T.J., Bishop J.A., Christadore L.M., Barot G., Chin H.G., Woodson S., et al. Antiproliferative small molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:4503-4508.
25. Hansen U., Owens L., Saxena U.H. Transcription factors LSF and E2Fs: Tandem cyclists driving G0 to S?. Cell Cycle 2009, 8:2146-2151.
26. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Reviews 1999, 20:761-787.
27. Ishizaki Y., Ikeda S., Fujimori M., Shimizu Y., Kurihara T., Itamoto T., et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. International Journal of Oncology 2004, 24:1077-1083.
28. Kang D.C., Su Z.Z., Sarkar D., Emdad L., Volsky D.J., Fisher P.B. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 2005, 353:8-15.
29. Kwun H.J., Jung E.Y., Ahn J.Y., Lee M.N., Jang K.L. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. The Journal of General Virology 2001, 82:2235-2241.
30. Lee S.G., Su Z.Z., Emdad L., Sarkar D., Fisher P.B. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:17390-17395.
31. Lee S.G., Su Z.Z., Emdad L., Sarkar D., Franke T.F., Fisher P.B. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 2008, 27:1114-1121.
32. Leung T.W., Patt Y.Z., Lau W.Y., Ho S.K., Yu S.C., Chan A.T., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clinical Cancer Research 1999, 5:1676-1681.
33. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Seminars in Liver Disease 1999, 19:329-338.
34. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003, 37:429-442.
35. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
36. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
37. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359:1734-1739.
38. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine 2008, 359:378-390.
39. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews. Cancer 2003, 3:330-338.
40. Majumder M., Ghosh A.K., Steele R., Ray R., Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. Journal of Virology 2001, 75:1401-1407.
41. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. European Journal of Cancer 2007, 43:979-992.
42. Meng X., Zhu D., Yang S., Wang X., Xiong Z., Zhang Y., et al. Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein. The Journal of Biological Chemistry 2012, 287:4485-4491.
43. Min L., He B., Hui L. Mitogen-activated protein kinases in hepatocellular carcinoma development. Seminars in Cancer Biology 2011, 21:10-20.
44. Murakami Y., Saigo K., Takashima H., Minami M., Okanoue T., Brechot C., et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54:1162-1168.
45. Oguri T., Achiwa H., Bessho Y., Muramatsu H., Maeda H., Niimi T., et al. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 2005, 49:345-351.
46. O'Neil B.H., Venook A.P. Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. The Oncologist 2007, 12:1425-1432.
47. Pang R.W., Joh J.W., Johnson P.J., Monden M., Pawlik T.M., Poon R.T. Biology of hepatocellular carcinoma. Annals of Surgical Oncology 2008, 15:962-971.
48. Paukku K., Kalkkinen N., Silvennoinen O., Kontula K.K., Lehtonen J.Y. p100 increases AT1R expression through interaction with AT1R 3'-UTR. Nucleic Acids Research 2008, 36:4474-4487.
49. Paukku K., Yang J., Silvennoinen O. Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcription 5. Molecular Endocrinology 2003, 17:1805-1814.
50. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
51. Poon R.T., Fan S.T., Lo C.M., Ng I.O., Liu C.L., Lam C.M., et al. Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Annals of Surgery 2001, 234:63-70.
52. Powell C.M., Rudge T.L., Zhu Q., Johnson L.F., Hansen U. Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. The EMBO Journal 2000, 19:4665-4675.
53. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Reviews. Immunology 2005, 5:215-229.
54. Ruan W., Xu E., Xu F., Ma Y., Deng H., Huang Q., et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biology & Therapy 2007, 6:354-359.
55. Santhekadur P.K., Das S.K., Gredler R., Chen D., Srivastava J., Robertson C., et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. The Journal of Biological Chemistry 2012, 287:13952-13958.
56. Santhekadur P.K., Gredler R., Chen D., Siddiq A., Shen X.N., Das S.K., et al. Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). The Journal of Biological Chemistry 2012, 287:3425-3432.
57. Santhekadur P.K., Rajasekaran D., Siddiq A., Gredler R., Chen D., Schaus S.E., et al. The transcription factor LSF: A novel oncogene for hepatocellular carcinoma. American Journal of Cancer Research 2012, 2:269-285.
58. Sarkar D., Park E.S., Emdad L., Lee S.G., Su Z.Z., Fisher P.B. Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Research 2008, 68:1478-1484.
59. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
60. Sprenger C.C., Damon S.E., Hwa V., Rosenfeld R.G., Plymate S.R. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Research 1999, 59:2370-2375.
61. Srivastava J., Siddiq A., Emdad L., Santhekadur P., Chen D., Gredler R., et al. Astrocyte elevated gene-1 (AEG-1) promotes hepatocarcinogenesis: Novel insights from a mouse model. Hepatology 2012, 56(5):1782-1791.
62. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010, 51:1820-1832.
63. Su Z.Z., Kang D.C., Chen Y., Pekarskaya O., Chao W., Volsky D.J., et al. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 2002, 21:3592-3602.
64. Teufel A., Staib F., Kanzler S., Weinmann A., Schulze-Bergkamen H., Galle P.R. Genetics of hepatocellular carcinoma. World Journal of Gastroenterology 2007, 13:2271-2282.
65. Thirkettle H.J., Mills I.G., Whitaker H.C., Neal D.E. Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene 2009, 28:3663-3670.
66. Thompson M.D., Monga S.P. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007, 45:1298-1305.
67. Tomimaru Y., Eguchi H., Wada H., Kobayashi S., Marubashi S., Tanemura M., et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. International Journal of Cancer 2012, 130:319-327.
68. Umemura T., Ichijo T., Yoshizawa K., Tanaka E., Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Journal of Gastroenterology 2009, 44(Suppl. 19):102-107.
69. Veljkovic J., Hansen U. Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 2004, 343:23-40.
70. Wajapeyee N., Serra R.W., Zhu X., Mahalingam M., Green M.R. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
71. Yang J., Aittomaki S., Pesu M., Carter K., Saarinen J., Kalkkinen N., et al. Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. The EMBO Journal 2002, 21:4950-4958.
72. Yang J.D., Roberts L.R. Hepatocellular carcinoma: A global view. Nature Reviews. Gastroenterology & Hepatology 2010, 7:448-458.
73. Yang J., Valineva T., Hong J., Bu T., Yao Z., Jensen O.N., et al. Transcriptional co-activator protein p100 interacts with snRNP proteins and facilitates the assembly of the spliceosome. Nucleic Acids Research 2007, 35:4485-4494.
74. Yeo W., Mok T.S., Zee B., Leung T.W., Lai P.B., Lau W.Y., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. Journal of the National Cancer Institute 2005, 97:1532-1538.
75. Yoo B.K., Chen D., Su Z.-Z., Gredler R., Yoo J., Shah K., et al. Molecular mechanism of chemoresistance by Astrocyte Elevated Gene-1 (AEG-1). Cancer Research 2010, 70:3249-3258.
76. Yoo B.K., Emdad L., Gredler R., Fuller C., Dumur C.I., Jones K.H., et al. Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:8357-8362.
77. Yoo B.K., Emdad L., Su Z.Z., Villanueva A., Chiang D.Y., Mukhopadhyay N.D., et al. Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. The Journal of Clinical Investigation 2009, 119:465-477.
78. Yoo B.K., Gredler R., Chen D., Santhekadur P.K., Fisher P.B., Sarkar D. c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF. Journal of Hepatology 2011, 55:1317-1324.
79. Yoo B.K., Gredler R., Vozhilla N., Su Z.Z., Chen D., Forcier T., et al. Identification of genes conferring resistance to 5-fluorouracil. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:12938-12943.
80. Yoo B.K., Santhekadur P.K., Gredler R., Chen D., Emdad L., Bhutia S.K., et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocelllular carcinoma. Hepatology 2011, 53:1538-1548.
81. Yoshinare K., Kubota T., Watanabe M., Wada N., Nishibori H., Hasegawa H., et al. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens. Cancer Science 2003, 94:633-638.
82. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
83. Zhu A.X., Blaszkowsky L.S., Ryan D.P., Clark J.W., Muzikansky A., Horgan K., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology 2006, 24:1898-1903.
84. Zhu K., Dai Z., Pan Q., Wang Z., Yang G.H., Yu L., et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clinical Cancer Research 2011, 17:7294-7302.